Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Sepsis drug put back at least two years

November 9, 2006 Research and Development

 AstraZeneca is being forced to conduct a second phase II trial on its sepsis drug, CytoFab.This follows discussions with US, …
News

‘Pulsed’ vitamin D drug could transform advanced prostate cancer treatment

November 9, 2006 Research and Development

American biotech company Novacea says it could be on the brink of revolutionising the prostate cancer market if phase III …
News

Novartis to be first pharma to conduct R&D in China

November 7, 2006 Research and Development Asia, China, Novartis, em

Novartis is to open a major, new pharmaceutical research and development centre in China, becoming the first company in the …
News

New clinical trials agreement to improve UK research

November 3, 2006 Research and Development

The Department of Health has revised its routine contract for industry-funded NHS clinical trials as a way of improving their …
News

GSK suffers pipeline setbacks

November 1, 2006 Research and Development

 A series of problems with GlaxoSmithKline's late stage product pipeline has taken the shine off its third quarter figures.The company …
News

Pharma’s evolving relationship with NICE

November 1, 2006 Research and Development, Sales and Marketing NHS, NICE, approval process, fast track, healthcare

Back when New Labour was only halfway through its first term of office and when the Millennium Bug was feared …
Feature

Modified mice could speed safe drug discoveries

October 27, 2006 Research and Development

 CXR Biosciences, based in Scotland, and Artemis Pharmaceuticals in Germany, have been granted licences to sell their genetically modified mice, …
News

Cerovive failure another blow for AstraZeneca

October 26, 2006 Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience

 A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …
News

Lilly underlines its position as major biotech company

October 25, 2006 Research and Development

Eli Lilly has opened the first phase of a $560 million expansion to its US biotech research complex.The news comes …
News

Pfizer buys British vaccine company PowderMed

October 12, 2006 Research and Development Pfizer, Powdermed, vaccines

Pfizer will gain entry into the fast-growing vaccines market by buying PowderMed, the British company developing next generation products in …
News

Amgen to acquire Avidia

October 5, 2006 Research and Development, Sales and Marketing

Amgen is to pay $290 million to buy Avidia, a Californian biotech company which is developing innovative new protein-based medicines.Based …
News

Novartis’ MS drug shows further promise

October 2, 2006 Research and Development

A new treatment for multiple sclerosis currently being developed by Novartis has shown further promise in slowing the progress of …
News

Two new AstraZeneca laboratories opened in UK

September 29, 2006 Research and Development

AstraZeneca has officially opened two major research laboratories in the UK, which it says demonstrates its commitment to R&D in …
News

AZ and Schering take novel approach in cancer collaboration

September 22, 2006 Research and Development

AstraZeneca and Schering are to co-develop a promising new drug candidate to treat breast cancer, with the two partners taking …
News

NicOx to develop enhanced statin product

September 6, 2006 Research and Development

NicOx is to develop a new statin treatment using its special in-house technology which, according to the company, could make …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026